Three-year (36.5 months minimum; 44.0 months median) follow-up results from the phase III CheckMate -9ER trial demonstrated sustained survival and response rate benefits with the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma, according to Bristol Myers Squibb and Exelixis Inc.
In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood.
